Skip to main content

Table 1 Characteristics HIV-infected multiparous mothers and their infants by previous exposure to single-dose nevirapine (SDNVP).

From: Reuse of single-dose nevirapine in subsequent pregnancies for the prevention of mother-to-child HIV transmission in Lusaka, Zambia: A cohort study

  Mother previously nevirapine exposed Mother previously nevirapine un-exposed p-value
Na 59 782  
Socio-demographic variables    
   Maternal age [mean ± SD] 27.3 ± 5.1 26.9 ± 4.9 0.59
   Number of previous live births [median (IQR)] 3 (2, 4) 2 (1, 3) 0.001
HIV-related factors at enrolment    
   HIV viral load [copies per ml ]    
Median (IQR) 20,501 (7,001; 60,617) 39,401 (9,728; 130,058) 0.04
< 10 000 [N (%)] 17 (29) 202 (26)  
10 000–99 999 [N (%)] 31 (53) 346 (44)  
≥ 100 000 [N (%)] 10 (17) 232 (30) 0.11 (trend)
   CD4 cells [counts per μl]    
Median (IQR) 335 (222, 453) 316 (190, 468) 0.86
< 200 14 (24) 205 (26)  
200–349 19 (33) 238 (30)  
≥ 350 25 (43) 338 (43) 0.86 (trend)
   N (%) WHO clinical stage III 11 (19) 337 (43) 0.0002
   BMI at 1 month post partum [mean ± SD] 22.7 ± 3.2 21.7 ± 3.4 0.03
   Hemoglobin [g/dl] [mean ± SD] 10.9 ± 1.5 10.6 ± 1.5 0.12
   Positive rapid plasma regain test for syphilis [N (%)] 6 (11) 135 (18) 0.15
Obstetric and infant variables    
   Caesarean sections [N (%)] 1 (2) 14 (2) 1.0
   Low birth weight [N (%) < 2500 g] 2 (4) 83 (11) 0.07
   Birth weight [mean ± SD] 3077 ± 439 3015 ± 496 0.36
   Preterm delivery [N (%) ≤ 34 weeks of gestation] 11 (19) 178 (23) 0.50
   Sex [N (%) male] 26 (44) 407 (52) 0.23
Nevirapine prophylaxis at current delivery    
   Maternal dose taken [N (%)] 58 (98) 745 (95) 0.51
   Infant dose taken [N (%)] 57 (98) 733 (95) 0.35
HIV transmission and infant mortalityb    
   Infants HIV positive ≤ day 42 [N (%)] 3 (5) 94 (12) 0.11
   Infants HIV positive or died ≤ day 42 [N (%)]c 4 (7) 127 (16) 0.06
  1. a) numbers may differ from the total due to missing data
  2. b) Loss to follow-up at 42 days (as defined as HIV-uninfected, did not die ≤ 42 days, but was last tested before the one month visit) was not significantly different between both groups (1 (2%) versus 63 (8%), p = 0.08).
  3. c) The study size for the combined analysis of infant mortality and HIV transmission was slightly larger as it includes 1 infant in the exposed and 18 in the unexposed group who died before the HIV status was established.